4.71 USD
▼-0.44-8.54%
盘后 4.79 +1.70%
2026-09-15
市值
$133.15M
市盈率
—
EPS
-1.56
股息率
—
52 周区间
3.71 – 8.74
成交量
1.69M
Beta
1.78
目标价
28.22
52W 低 3.7152W 高 8.74
价格走势
公司简介
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney inj...